Gadoxetic acid enhanced MRI for differentiation of FNH and HCA: a single centre experience

Evaluation of enhancement characteristics of histopathologically confirmed focal nodular hyperplasias (FNHs) and hepatocellular adenomas (HCAs) with gadoxetic acid-enhanced MRI. Sixty-eight patients with 115 histopathologically proven lesions (FNHs, n = 44; HCAs, n = 71) examined with gadoxetic acid-enhanced MRI were retrospectively enrolled (standard of reference: surgical resection, n = 53 patients (lesions: FNHs, n = 37; HCAs, n = 53); biopsy, n = 15 (lesions: FNHs, n = 7; HCAs, n = 18)). Two radiologists evaluated all MR images regarding morphological features as well as the vascular and hepatocyte-specific enhancement in consensus. For the hepatobiliary phase, relative enhancement of the lesions and lesion to liver enhancement were significantly lower for HCAs (mean, 48.7 (+/- 48.4) % and 49.4 (+/- 33.9) %) compared to FNHs (159.3 (+/- 92.5) %; and 151.7 (+/- 79) %; accuracy of 89 % and 90 %, respectively; P < 0.001). Visual strong uptake of FNHs vs. hypointensity of HCAs in the hepatobiliary phase resulted in an accuracy of 92 %. This parameter was superior to all other morphological and dynamic vascular criteria alone and in combination (accuracy, 54-85 %). For differentiation of FNHs and HCAs by means of MRI, gadoxetic acid uptake in the hepatobiliary phase was found to be superior to all other criteria alone and in combination. aEuro cent EOB-MRI is well suited to differentiate FNHs and hepatocellular adenomas. aEuro cent For this purpose hepatobiliary phase is superior to unenhanced and dynamic imaging. aEuro cent Hepatobiliary phase (peripheral) hyper- or isointensity is typical for FNH. aEuro cent Hepatobiliary phase hypointensity is typical for hepatocellular adenomas. aEuro cent EOB-MRI helps to avoid misinterpretations of benign hepatocellular lesions.